Michael Muteti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Muteti has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Adrian B. McDermott
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
1 shared publication - Adrienne E. Shapiro
University of Washington
1 shared publication - Alessia Liguori
Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA
1 shared publication - Alison Benner
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
1 shared publication - Allan C. Decamp
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
1 shared publication Allison Kennedy
IAVI, New York, NY, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadr8382
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.
- 31 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6759) , eadr8382
Top Cited PapersOpen AccessVaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans
A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI G002 in the United States and IAVI G003 in Rwanda and South Africa (IAVI, International Aids Vaccine Initiative), we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI G002). The vaccines were generally safe and well tolerated, except that 18% of IAVI G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM; heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development; and elicited antibodies exhibited precise bnAb structural mimicry. The results establish clinical proof of concept that heterologous boosting can advance bnAb precursor maturation and demonstrate bnAb priming in Africa, where the HIV burden is highest.
- Open Access
- 14 June 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 1 (2)
Erythrocyte alloimmunization in children with sickle cell anemia living in Kilifi, Kenya
- 14 June 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 1 (2)
Open AccessErythrocyte alloimmunization in children with sickle cell anemia living in Kilifi, Kenya